Courses

Differentiating S1P-Based Therapeutics for the Treatment of Patients with Multiple Sclerosis
Neurology

Differentiating S1P-Based Therapeutics for the Treatment of Patients with Multiple Sclerosis

This CME program will highlight recent advances in S1P-based therapeutics for the treatment of patients with multiple sclerosis. The expert faculty, Dr. Clyde Markowitz, will first review the pharmacologic characteristics of all S1P-based therapies to aid in clinical decision making for the early intervention of patients diagnosed with multiple sclerosis (MS). Following, he will discuss long term efficacy and safety ...
View Course

Review of New and Emerging Therapies that Improve Tolerability and Adherence in Patients with Relapsing Multiple Sclerosis
Neurology

Review of New and Emerging Therapies that Improve Tolerability and Adherence in Patients with Relapsing Multiple Sclerosis

This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, Dr. Aaron Miller, will start by analyzing the unmet needs for patients with relapsing multiple sclerosis (RMS) including tolerance and adherence to long-term treatment. Following, he will review the clinical trial data for new and emerging injectable therapies, including glatiramer ...
View Course

Brain Penetrant BTK Update: Reducing Neuroinflammation to Optimize Outcomes for Patients with Multiple Sclerosis
Neurology

Brain Penetrant BTK Update: Reducing Neuroinflammation to Optimize Outcomes for Patients with Multiple Sclerosis

This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, Dr. Fred Lublin, will first analyze current clinical trial data for BTK therapeutics to manage patients with multiple sclerosis. Following, he will review strategies for patient education, shared decision making, and overcoming barriers to treatment adherence. To conclude, Dr. Lublin ...
View Course

Clinical Update on Anti-CD20 Therapeutics for Patients with Relapsing Multiple Sclerosis
Neurology

Clinical Update on Anti-CD20 Therapeutics for Patients with Relapsing Multiple Sclerosis

This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, led by Dr. Mark Freedman, will first cover the topic of b-cells and anti-CD20 as therapeutic targets in the multiple sclerosis (MS) treatment landscape. Following, recent clinical trial data of anti-CD20 monoclonal antibody therapeutics to treat patients with relapsing multiple ...
View Course
Update on Advanced Anti-CD20 Therapeutics to Improve Outcomes for Patients with Multiple Sclerosis
Neurology

Update on Advanced Anti-CD20 Therapeutics to Improve Outcomes for Patients with Multiple Sclerosis

This CME program will highlight updates in the multiple sclerosis treatment landscape, including anti-CD20 therapeutics. The expert faculty, Dr. Grace Gombolay, will first utilize a case-based format to review current guidelines as well as the typical clinical course in multiple sclerosis. Following, recent clinical trial data of both B-cell depleting and anti-CD20 therapeutics will be analyzed, along with the implications ...
View Course
The New Era of Biosimilar Therapeutics for Multiple Sclerosis
Neurology

The New Era of Biosimilar Therapeutics for Multiple Sclerosis

This CME program is derived from content presented at the Advanced Curriculum for Multiple Sclerosis 2024 Course. The expert faculty, led by Dr. Jiwon Oh, will first provide an overview of biosimilar development, including an explanation of the steps for a proposed biosimilar antibody. Following, recent clinical trial data in the biosimilar treatment landscape will be reviewed, including drugs in ...
View Course
Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis
Neurology

Update for Hospital and Health-System Pharmacists on Newer Therapeutics to Optimize Management of Patients with Generalized Myasthenia Gravis

About 85% of patients with generalized myasthenia gravis (gMG)--an autoimmune disease of the neuromuscular junction caused by antibodies that attack components of the postsynaptic membrane, impair neuromuscular transmission, and therefore cause weakness and fatigue of skeletal and bulbar muscles--have demonstrable IgG autoantibodies.  These autoantibodies exert a direct pathogenic effect that results in impaired neuromuscular transmission.  Most currently available treatments, including ...
View Course
Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis
Neurology

Clinical Update for Individualized Treatment Plans for Patients with Generalized Myasthenia Gravis

Patients with generalized myasthenia gravis (gMG) experience significant and heterogeneous symptomatology, placing a substantial burden on their quality of life including physical, emotional, and work/financial aspects. Recent clinical trial data are showing that the utilization of individualized dosing including holding treatment during periods of stability can be effective and safe. It is important for clinicians to assess these data and ...
View Course
Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG
Neurology

Improving Systematic Monitoring for Glucocorticoid Adverse Events to Guide Appropriate Use of Steroid-Sparing Therapy in Patients with gMG

Myasthenia gravis is one of the oldest recognized autoimmune neurologic diseases, but practice-changing clinical trials remain challenging despite greater knowledge of pathophysiology. Both incidence and prevalence of the disease have increased over the years because of greater awareness of MG, better application of diagnostic testing, and better quality of epidemiologic studies. Corticosteroids were introduced as treatment for MG in the 1950s ...
View Course

Advances in Disease Management of Generalized Myasthenia Gravis
Neurology

Advances in Disease Management of Generalized Myasthenia Gravis

This CME program will highlight recent advances in disease management of generalized myasthenia gravis (MG). The expert faculty, led by Dr. Vera Bril, will first outline the pathophysiology of myasthenia gravis, detailing epidemiology, pathogenesis and the case for targeted treatments. Following, current clinical trial data for FcRn inhibitors in MG will be analyzed, including a review of mechanisms of action ...
View Course